| abstract |
The present invention is an essential component comprising at least one active substance selected from bisphosphonate-based drugs having ionization in vivo and high water solubility, which does not pass through the biolipid membrane, and has a bioavailability of less than 10%, and at least one selected from biocompatible water-soluble chitosan. It relates to a pharmaceutical composition for improving the oral absorption of bisphosphonate-based drugs as a pharmaceutical composition.n n n n Bisphosphonates, Water Soluble Chitosan, Bioavailability |